Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.
Mughal TI, Lion T, Abdel-Wahab O, Mesa R, Scherber RM, Perrotti D, Mauro M, Verstovsek S, Saglio G, Van Etten RA, Kralovics R. Mughal TI, et al. Among authors: lion t. Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3. Hematol Oncol. 2018. PMID: 30074634 Free PMC article. Review.
Illuminating novel biological aspects and potential new therapeutic approaches for chronic myeloproliferative malignancies.
Mughal TI, Pemmaraju N, Psaila B, Radich J, Bose P, Lion T, Kiladjian JJ, Rampal R, Jain T, Verstovsek S, Yacoub A, Cortes JE, Mesa R, Saglio G, van Etten RA. Mughal TI, et al. Among authors: lion t. Hematol Oncol. 2020 Dec;38(5):654-664. doi: 10.1002/hon.2771. Epub 2020 Sep 4. Hematol Oncol. 2020. PMID: 32592408 Free PMC article. Review.
Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions.
Valent P, Orfao A, Kubicek S, Staber P, Haferlach T, Deininger M, Kollmann K, Lion T, Virgolini I, Winter G, Hantschel O, Kenner L, Zuber J, Grebien F, Moriggl R, Hoermann G, Hermine O, Andreeff M, Bock C, Mughal T, Constantinescu SN, Kralovics R, Sexl V, Skoda R, Superti-Furga G, Jäger U. Valent P, et al. Among authors: lion t. Hemasphere. 2021 Feb 17;5(3):e536. doi: 10.1097/HS9.0000000000000536. eCollection 2021 Mar. Hemasphere. 2021. PMID: 33623882 Free PMC article. Review.
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia.
Cross NC, White HE, Colomer D, Ehrencrona H, Foroni L, Gottardi E, Lange T, Lion T, Machova Polakova K, Dulucq S, Martinelli G, Oppliger Leibundgut E, Pallisgaard N, Barbany G, Sacha T, Talmaci R, Izzo B, Saglio G, Pane F, Müller MC, Hochhaus A. Cross NC, et al. Among authors: lion t. Leukemia. 2015 May;29(5):999-1003. doi: 10.1038/leu.2015.29. Epub 2015 Feb 5. Leukemia. 2015. PMID: 25652737 Free PMC article. Review.
A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.
Heibl S, Buxhofer-Ausch V, Schmidt S, Webersinke G, Lion T, Piringer G, Kuehr T, Wolf D, Melchardt T, Greil R, Thaler J. Heibl S, et al. Among authors: lion t. Hematol Oncol. 2020 Dec;38(5):792-798. doi: 10.1002/hon.2786. Epub 2020 Aug 19. Hematol Oncol. 2020. PMID: 32757230 Clinical Trial.
CDK4/CDK6 inhibition as a novel strategy to suppress the growth and survival of BCR-ABL1T315I+ clones in TKI-resistant CML.
Schneeweiss-Gleixner M, Byrgazov K, Stefanzl G, Berger D, Eisenwort G, Lucini CB, Herndlhofer S, Preuner S, Obrova K, Pusic P, Witzeneder N, Greiner G, Hoermann G, Sperr WR, Lion T, Deininger M, Valent P, Gleixner KV. Schneeweiss-Gleixner M, et al. Among authors: lion t. EBioMedicine. 2019 Dec;50:111-121. doi: 10.1016/j.ebiom.2019.11.004. Epub 2019 Nov 21. EBioMedicine. 2019. PMID: 31761618 Free PMC article.
199 results